Vedanta Biosciences Granted Second U.S. Patent Covering Methods of Treating Autoimmune Disease
The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,421,230. The patent broadly covers methods of treating autoimmune disease with mixtures of Clostridium live bacterial strains.
The patented technology is based on ground-breaking work by Dr. Kenya Honda, a scientific co-founder of Vedanta. Dr. Honda’s work shows that compositions of bacterial strains belonging to Clostridium clusters IV and/or XIVa may potentially be used to treat a range of autoimmune diseases, such as ulcerative colitis, Crohn’s disease or graft versus host disease.
Vedanta Biosciences develops a novel class of therapies designed to modulate pathways of interaction between the human microbiome and the host immune system, with clinical trials in certain indications expected to begin in the first half of 2017.